Novonesis to Fully Acquire MicroBioGen for Bioethanol Yeast Expertise — Novonesis A/S

Event summary

Novonesis to acquire remaining stake in MicroBioGen, an Australian biotech firm specializing in industrial yeast strains for bioethanol production.
The deal builds on Novonesis' existing 23% ownership since a 2013 investment and over a decade of collaboration with MicroBioGen.
Transaction terms undisclosed; completion subject to ACCC regulatory approval.
MicroBioGen's technology includes the Innova® yeast series, co-developed with Novonesis for industrial applications.

The big picture

This acquisition strengthens Novonesis' position in the bioethanol sector by consolidating its control over a key yeast technology partner. The move aligns with broader industry trends toward sustainable energy solutions, where microbial innovation is critical. With approximately 10% of annual sales invested in R&D, Novonesis is doubling down on biological solutions to meet growing demand for efficient industrial fermentation processes.

What we're watching

Integration Challenges: How Novonesis will integrate MicroBioGen's technology and talent into its existing operations.
Regulatory Approval: The pace at which ACCC approval is secured, given the deal's cross-border nature.
Strategic Alignment: Whether this acquisition accelerates Novonesis' 2030 strategy in bioethanol and other industrial applications.